Menopause & Hormonal Health stem cell therapy — your questions answered (2026)

About stem cell therapy for Menopause & Hormonal Health

Menopause is a life transition associated with changing ovarian hormone levels and symptoms that may include hot flushes, night sweats, sleep disturbance, mood symptoms and genitourinary symptoms. Evidence-based management is individualised and may include hormone therapy, non-hormonal medicines, menopause-specific cognitive behavioural therapy and local treatments depending on symptoms and risk factors. Mesenchymal stromal cells (MSCs) and extracellular vesicles are experimental and have not established hormonal restoration, tissue rejuvenation or clinical equivalence to recommended treatment. The registry table on this page lists relevant studies and their current recruitment status.

The evidence for Menopause & Hormonal Health

Evidence for cell or exosome treatment of menopause symptoms is sparse and does not establish comparative efficacy or long-term safety. Small uncontrolled subjective reports cannot distinguish treatment effects from placebo, natural symptom change or concurrent care. Mechanistic or inflammatory-marker findings are not substitutes for validated symptom and safety outcomes. No pooled response rate is published here. The registered studies and their own prespecified endpoints are listed in the registry table on this page.

Private investigational menopause cell or exosome procedures can involve separate charges for consultation, testing, repeat administration, monitoring and travel. Prices do not indicate regulatory approval or advantage over established treatment. Patients should request an itemised written quote and verify sponsor, insurer and patient responsibilities. A clinician should first discuss evidence-based hormonal and non-hormonal options and individual contraindications.

What does cell-based menopause support involve?

Cell therapy for Menopause & Hormonal Health may be offered as an individualised programme, but regulatory status depends on the product, processing, indication and jurisdiction. It is currently investigational. Verify authorisation status, cell source, release testing and clinical evidence for the specific proposal.

Is it hormone therapy?

Schedules vary by the exact product, protocol, route, monitoring needs and clinical context. Request the proposed schedule and its evidence before making travel arrangements.

How long do effects last?

Eligibility depends on the protocol's inclusion and exclusion criteria and an appropriately qualified clinician's assessment. An online checklist cannot determine candidacy or replace medical advice.

EU cost?

The partner-published indicative range for an Menopause & Hormonal Health programme is €3,000–€8,000 for treatment. Request a current written quotation and compare product, dose, visits, inclusions and follow-up before using country ranges as a benchmark.

Sources & further reading

We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.

• Open clinical trials for Menopause & Hormonal Health (ClinicalTrials.gov) ↗
• Peer-reviewed research on PubMed ↗
• ISSCR patient guide — what to ask ↗
• FDA consumer warning on stem-cell therapies ↗
• EMA — advanced-therapy (ATMP) framework ↗

← Back to Menopause & Hormonal Health overview · Menopause & Hormonal Health cost →